Resolve's lead molecule is RSLV-132, a fully human RNase-Fc fusion protein. The compound has successfully completed a single dose safety study in 32 healthy volunteers and a multi-dose safety study in 32 patients with SLE. We are currently conducting a phase 2 SLE study with 50 patients at clinical centers throughout the United States. The study is focusing on patients with active skin disease and elevated RNA autoantibodies.
Results of a study in patients with primary Sjögren’s Syndrome showed that RSLV-132 statistically significantly improved symptoms of fatigue as compared to placebo, was safe and well-tolerated, and that further investigation of its use in pSS is warranted. These data are being presented at an oral session, which is also included in the Clinical Highlights Session, at the 2019 European League Against Rheumatism (EULAR) European Congress of Rheumatology in Madrid, Spain.
Bi-Specific Nuclease Platform
This class of molecules have both RNase and DNase enzymatic activity. The molecules are full human Fc fusion proteins consisting of both RNase and DNase. The lead molecule in this class is RSLV-133 which is currently in the pre-clinical stage of development. This molecule will be tested in lupus nephritis where the both RNA and DNA-containing immune complexes contribute to kidney damage.